Cite
Ostwal V, Sahu A, Ramaswamy A, et al. Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. J Gastric Cancer. 2017;17(1):21-32doi: 10.5230/jgc.2017.17.e3.
Ostwal, V., Sahu, A., Ramaswamy, A., Sirohi, B., Bose, S., Talreja, V., Goel, M., Patkar, S., Desouza, A., & Shrikhande, S. V. (2017). Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. Journal of gastric cancer, 17(1), 21-32. https://doi.org/10.5230/jgc.2017.17.e3
Ostwal, Vikas, et al. "Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis." Journal of gastric cancer vol. 17,1 (2017): 21-32. doi: https://doi.org/10.5230/jgc.2017.17.e3
Ostwal V, Sahu A, Ramaswamy A, Sirohi B, Bose S, Talreja V, Goel M, Patkar S, Desouza A, Shrikhande SV. Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. J Gastric Cancer. 2017 Mar;17(1):21-32. doi: 10.5230/jgc.2017.17.e3. Epub 2017 Mar 16. PMID: 28337360; PMCID: PMC5362831.
Copy
Download .nbib